A significant health alert has emerged following a nationwide recall of a widely used eczema treatment cream due to concerns over potential bacterial contamination. Pharmacal, the company behind MG217 Multi-Symptom Treatment Cream & Skin Protectant Eczema Cream, has announced the recall of a specific lot of the product after it was found to be contaminated with Staphylococcus aureus, commonly referred to as staph bacteria.
:max_bytes(150000):strip_icc():format(jpeg)/dermatology-2-1ab292b9340344a0b2839dc27f7141f1.jpg)
The recalled product comes in a 6-ounce tube labelled with lot number 1024088, which is set to expire in November 2026. Consumers can locate the lot number printed on the crimped end of the tube. This particular lot was sold through various channels, including wholesalers, grocery stores, and online retailers such as Amazon, making it widely accessible to the public.
In light of the findings, the U.S. Food and Drug Administration (FDA) has issued a warning regarding the cream’s potential to cause serious health issues if used. The agency cautioned that using the contaminated cream could result in infections that range from mild skin irritations to severe conditions that may be life-threatening.
Pharmacal emphasised that individuals should stop using the affected cream immediately and dispose of it properly. The MG217 cream is marketed for alleviating eczema symptoms, including itching, dryness, redness, cracking, and irritation, and is promoted as fragrance-free, steroid-free, and hypoallergenic.
The FDA has specifically alerted individuals with compromised immune systems or pre-existing skin conditions, such as burns or eczema, of their heightened risk for severe complications. Possible infections linked to the contaminated cream can include serious conditions like bloodstream infections, bone and joint infections, heart valve infections, and even sepsis or septic shock.
According to the Centres for Disease Control and Prevention (CDC), staph bacteria are commonly found on human skin and within the nasal passages of many individuals, typically without causing issues. However, in those with weakened immune systems or underlying health conditions, these bacteria can lead to significant infections, manifesting as boils, pimples, or more severe problems that may spread to critical areas, including the bloodstream, lungs, and bones.
Despite the seriousness of the situation, Pharmacal has reported no illnesses or adverse reactions related to this recall as of yet. Nevertheless, the FDA has advised consumers who may have experienced any health complications associated with the cream to seek guidance from their healthcare providers.
Pharmacal has made resources available for consumers who have questions or concerns about the recall. Individuals can contact the company directly at 800-558-6614 or via email at aimho@pharmacalway.com during business hours, Monday through Friday, from 8 a.m. to 5 p.m. Central Time.
As consumers navigate this disturbing news, it is crucial to stay informed and take the necessary precautions regarding their health and safety. Regular updates will be vital as this situation develops, and organisations like the FDA and Pharmacal remain at the forefront, ensuring public awareness and health protection.